In the rapidly evolving field of regenerative medicine, REPROCELL’s StemRNATM Clinical iPSCs provide a benchmark for clinical grade induced pluripotent stem cells (iPSCs). These high-quality iPSCs provide a foundation for various cell therapy programs, ensuring safety, consistency, and regulatory compliance. Our clinical iPSCs are currently being evaluated by many biopharma companies globally, are selected for regulatory filings and are IND approved. REPROCELL is a trusted partner for cell therapy developers who are seeking robust, high-quality clinical iPSC banks that meet industry standards. [Read more…]
REPROCELL’s Clinical-Grade iPSCs:
I Peace establishes and offers low immunoreaction risk GMP iPS Cells
Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product
February 5, 2025, Palo Alto, CA – Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP iPSCs derived from type O female blood and started offering as an off-the-shelf product. [Read more…]
How iPSCs are Becoming an Emerging Area of Stem Cell Research
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged. Included below is a ten-year history of iPSC grants (source: RePORT.NIH.gov), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov).
Both graphs below reveal the iPSC market is expanding. [Read more…]
Cellectricon and Censo Launch Human iPSC-based Discovery Services for CNS and Pain Research
Cellectricon and Censo Biotechnologies Introduce a Joint Technology Access Program
High-quality Human iPSC-based discovery services for CNS and pain research.
| January 26, 2017 –Â Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research. [Read more…]
Roslin Stem Cell Companies Combine to Create Censo Biotechnologies Group
Edinburgh, UK. 10 May 2016 — The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focused on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary.
Censo Biotechnologies has extensive capacity to create and use induced Pluripotent Stem Cells (iPSCs) for drug discovery research with sites in Edinburgh and Cambridge, UK. The Company uses this capacity to produce stem cells from large diverse groups of individuals, so that drug development companies can understand how the efficacy of their drugs varies across the population. This underpins faster drug development and enables the right drug to be targeted to the right patient. [Read more…]